Phio Pharmaceuticals (PHIO) Revenue & Revenue Breakdown
Phio Pharmaceuticals Revenue Highlights
00
Phio Pharmaceuticals Revenue by Period
Phio Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $21.00K | -84.78% |
| 2018-12-31 | $138.00K | 820.00% |
| 2017-12-31 | $15.00K | -21.05% |
| 2016-12-31 | $19.00K | -44.12% |
| 2015-12-31 | $34.00K | -52.11% |
| 2014-12-31 | $71.00K | -82.21% |
| 2013-12-31 | $399.00K | 311.34% |
| 2012-12-31 | $97.00K | 100.00% |
| 2011-12-31 | - | - |
Phio Pharmaceuticals generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Phio Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $70.00K | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $30.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | -100.00% |
| 2019-03-31 | $21.00K | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2018-09-30 | $57.00K | -1.72% |
| 2018-06-30 | $58.00K | 152.17% |
| 2018-03-31 | $23.00K | 53.33% |
| 2017-12-31 | $15.00K | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $9.00K | -10.00% |
| 2016-03-31 | $10.00K | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | -100.00% |
| 2015-03-31 | $34.00K | 142.86% |
| 2014-12-31 | $14.00K | -12.50% |
| 2014-09-30 | $16.00K | 33.33% |
| 2014-06-30 | $12.00K | -58.62% |
| 2014-03-31 | $29.00K | - |
| 2013-12-31 | $29.00K | -68.48% |
| 2013-09-30 | $92.00K | -59.11% |
| 2013-06-30 | $225.00K | 324.53% |
| 2013-03-31 | $53.00K | 32.50% |
| 2012-12-31 | $40.00K | -29.82% |
| 2012-09-30 | $57.00K | 100.00% |
| 2012-06-30 | - | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | - |
Phio Pharmaceuticals generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Phio Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| MRKR | Marker Therapeutics | $6.59T | $861.18K |
| KPRX | Kiora Pharmaceuticals | $16.02M | - |
| CELZ | Creative Medical Technology | $11.00K | - |
| APRE | Aprea Therapeutics | - | $118.11K |
| GLTO | Galecto | - | - |
| ACXP | Acurx Pharmaceuticals | - | - |
| PHIO | Phio Pharmaceuticals | - | - |
| RNAZ | TransCode Therapeutics | - | - |
| INAB | IN8bio | - | - |
| APVO | Aptevo Therapeutics | - | - |
| BCDA | BioCardia | - | - |